Good morning, you're tuned into Markets Desk.
BT Group is reshaping its international footprint this morning, announcing a fifty-fifty joint venture with Verizon Communications that will merge both companies' international enterprise operations into a single entity focused on serving multinational clients. The deal comes at a cost to near-term guidance, with BT revising its annual outlook downward to absorb the structural impact of folding those operations into the new partnership. Investors will be watching closely to see whether the long-term strategic logic outweighs the short-term earnings drag.
Shifting to housing, a new Harvard study is making waves well beyond the usual affordability conversation. The report's deeper argument is a striking one — that the era of broad middle-class homeownership in America was never a structural guarantee, but rather a historical anomaly built on postwar policy conditions that have since unwound. For markets tied to residential real estate, that framing carries real long-term implications.
And in vaccine approvals, Bavarian Nordic has secured Health Canada clearance for VIMKUNYA, its chikungunya vaccine, now authorized for individuals twelve years of age and older. The approval extends the company's commercial reach into Canada following prior clearances elsewhere, adding another revenue pathway for a company that has been steadily building its infectious disease portfolio.
That's the tape. Markets Desk, signing off the floor.
